CN1511036B - 包含信号转导抑制剂和埃坡霉素衍生物的联合形式 - Google Patents

包含信号转导抑制剂和埃坡霉素衍生物的联合形式 Download PDF

Info

Publication number
CN1511036B
CN1511036B CN028056086A CN02805608A CN1511036B CN 1511036 B CN1511036 B CN 1511036B CN 028056086 A CN028056086 A CN 028056086A CN 02805608 A CN02805608 A CN 02805608A CN 1511036 B CN1511036 B CN 1511036B
Authority
CN
China
Prior art keywords
combination
methyl
epothilone
lower alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN028056086A
Other languages
English (en)
Chinese (zh)
Other versions
CN1511036A (zh
Inventor
R·勃兰特
E·布赫东格尔
C-H·赫尔迪恩
A·厄斯特曼
K·彼得拉斯
T·奥赖利
J·D·罗瑟梅尔
P·特拉克斯勒
M·瓦特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0104840.4A external-priority patent/GB0104840D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1511036A publication Critical patent/CN1511036A/zh
Application granted granted Critical
Publication of CN1511036B publication Critical patent/CN1511036B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN028056086A 2001-02-27 2002-02-26 包含信号转导抑制剂和埃坡霉素衍生物的联合形式 Expired - Fee Related CN1511036B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0104840.4 2001-02-27
GBGB0104840.4A GB0104840D0 (en) 2001-02-27 2001-02-27 Use of organic compounds
US33904001P 2001-10-30 2001-10-30
US60/339,040 2001-10-30
PCT/EP2002/002049 WO2002067941A2 (en) 2001-02-27 2002-02-26 Combination comprising a signal transduction inhibitor and an epothilone derivative

Publications (2)

Publication Number Publication Date
CN1511036A CN1511036A (zh) 2004-07-07
CN1511036B true CN1511036B (zh) 2010-05-05

Family

ID=26245767

Family Applications (1)

Application Number Title Priority Date Filing Date
CN028056086A Expired - Fee Related CN1511036B (zh) 2001-02-27 2002-02-26 包含信号转导抑制剂和埃坡霉素衍生物的联合形式

Country Status (22)

Country Link
US (1) US7723339B2 (https=)
EP (1) EP1385522B1 (https=)
JP (1) JP4499359B2 (https=)
KR (1) KR100848197B1 (https=)
CN (1) CN1511036B (https=)
AT (1) ATE434438T1 (https=)
AU (1) AU2002308218B2 (https=)
BR (1) BR0207649A (https=)
CA (1) CA2439268C (https=)
CY (1) CY1109347T1 (https=)
DE (1) DE60232719D1 (https=)
DK (1) DK1385522T3 (https=)
ES (1) ES2326264T3 (https=)
IL (2) IL157466A0 (https=)
MX (1) MXPA03007729A (https=)
NO (1) NO325416B1 (https=)
NZ (1) NZ527764A (https=)
PL (1) PL207197B1 (https=)
PT (1) PT1385522E (https=)
RU (1) RU2313345C2 (https=)
SK (1) SK287489B6 (https=)
WO (1) WO2002067941A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
IL157443A0 (en) 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
CA2444867C (en) * 2001-05-16 2010-08-17 Novartis Ag Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
EP1704863A3 (en) * 2001-05-16 2010-11-24 Novartis AG Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent
EP1441736A2 (en) * 2001-10-29 2004-08-04 Novartis AG Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2186811A1 (en) 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
US7754850B2 (en) 2005-02-11 2010-07-13 University Of Southern California Chimeric disintegrin domain
EP2029156A4 (en) * 2006-05-01 2010-07-21 Univ Southern California COMBINATION THERAPY FOR CANCER TREATMENT
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1077713A (zh) * 1992-04-03 1993-10-27 希巴-盖吉股份公司 嘧啶衍生物及其制备方法
CN1194647A (zh) * 1995-07-06 1998-09-30 诺瓦蒂斯有限公司 吡咯并嘧啶及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
ES2312695T3 (es) 1996-11-18 2009-03-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epotilones e y f.
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
WO2000000485A1 (de) * 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
HK1044946A1 (zh) * 1999-02-11 2002-11-08 舍林股份公司 依泊昔酮衍生物、其製備方法及藥物用途
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1077713A (zh) * 1992-04-03 1993-10-27 希巴-盖吉股份公司 嘧啶衍生物及其制备方法
CN1194647A (zh) * 1995-07-06 1998-09-30 诺瓦蒂斯有限公司 吡咯并嘧啶及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
作者:Nicolaou, K. et al..标题:Synthesis and biological properties ofC12,13-cyclopropyl-epothilone A and related epothilones..Chem. Biol.卷号：5 期号：7.1998,5(7),365-372.
作者:Nicolaou,K.et al..标题:Synthesis and biological properties ofC12,13-cyclopropyl-epothilone A and related epothilones..Chem. Biol.卷号：5 期号：7.1998,5(7),365-372. *

Also Published As

Publication number Publication date
KR20040025900A (ko) 2004-03-26
JP2004527493A (ja) 2004-09-09
PT1385522E (pt) 2009-09-04
WO2002067941A8 (en) 2003-12-18
KR100848197B1 (ko) 2008-07-24
CA2439268C (en) 2010-01-19
NO325416B1 (no) 2008-04-21
RU2003127392A (ru) 2005-03-27
WO2002067941A2 (en) 2002-09-06
NO20033769L (no) 2003-08-25
SK287489B6 (sk) 2010-11-08
CN1511036A (zh) 2004-07-07
IL157466A0 (en) 2004-03-28
DE60232719D1 (de) 2009-08-06
CY1109347T1 (el) 2014-07-02
AU2002308218B2 (en) 2005-11-10
RU2313345C2 (ru) 2007-12-27
NO20033769D0 (no) 2003-08-25
JP4499359B2 (ja) 2010-07-07
ATE434438T1 (de) 2009-07-15
NZ527764A (en) 2006-01-27
DK1385522T3 (da) 2009-10-12
HK1062266A1 (en) 2004-10-29
EP1385522A2 (en) 2004-02-04
IL157466A (en) 2012-04-30
MXPA03007729A (es) 2003-12-04
ES2326264T3 (es) 2009-10-06
WO2002067941A3 (en) 2003-11-20
US7723339B2 (en) 2010-05-25
EP1385522B1 (en) 2009-06-24
CA2439268A1 (en) 2002-09-06
SK10712003A3 (sk) 2004-02-03
BR0207649A (pt) 2004-03-09
US20040132754A1 (en) 2004-07-08
PL207197B1 (pl) 2010-11-30
PL363288A1 (en) 2004-11-15

Similar Documents

Publication Publication Date Title
CN1511036B (zh) 包含信号转导抑制剂和埃坡霉素衍生物的联合形式
US20060270665A1 (en) Combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity
JP2006503867A (ja) 癌を処置するための相乗的な方法および組成物
WO2010031265A1 (zh) 用于治疗增生性疾病的药物组合物
AU2002308218A1 (en) Combination comprising a signal transduction inhibitor and an epothilone derivative
US20110281902A1 (en) Combinations comprising a protein kinase inhibitor being a pyrimidylaminobenzamide compound and a hsp90 inhibitor such as 17-aag
TW201006823A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
JP2012510444A (ja) 治療的処置のためのＨｓｐ９０阻害剤
JP2013035853A (ja) 増殖性疾患の処置または予防のためのピリミジルアミノベンズアミド化合物とイマチニブの組み合わせ
NZ550174A (en) Combinations comprising a vasculostatic compound such as vatalanib and epothilones, and pharmaceutical uses thereof
CN102227227B (zh) 包含吡啶并[4，3-d]嘧啶衍生的HSP90抑制剂和HER2抑制剂的药物组合
JP4429732B2 (ja) 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤
TWI343258B (en) Combination comprising an active ingredient which decreases the activity of the epidermal growth factor (egf) and an epothilone derivative
HK1062266B (en) Combination comprising a signal transduction inhibitor and an epothilone derivative

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100505

Termination date: 20140226